The value of precision oncology initiatives in Asian contexts remains unresolved. Here, we review the institutional implementation of prospective molecular screening to facilitate accrual of patients into biomarker-driven clinical trials, and to explore the mutational landscape of advanced tumors occurring in a prospective cohort of Asian patients (n 5 396) with diverse cancer types. Next-generation sequencing (NGS) and routine clinicopathological assays, such as immunohistochemistry, copy number analysis and in situ hybridization tests, were performed on tumor samples. Actionable biomarker results were used to identify eligibility for early-phase, biomarker-driven clinical trials. Overall, NGS was successful in 365 of 396 patients (92%), achieving a mean depth of 1,9433 and coverage uniformity of 96%. The median turnaround time from sample receipt to return of genomic results was 26.0 days (IQR, 19.0-39.0 days). Reportable mutations were found in 300 of 365 patients (82%). Ninety-one percent of patients at study enrollment indicated consent to receive incidental findings and willingness to undergo genetic counseling if required. The most commonly mutated oncogenes included KRAS (19%), PIK3CA (16%), EGFR (5%), BRAF (3%) and KIT (3%); while the most frequently mutated tumor suppressor genes included TP53 (40%), SMARCB1 (12%), APC (8%), PTEN (6%) and SMAD4 (5%). Among 23 patients enrolled in genotype-matched trials, median progression-free survival was 2.9 months (IQR, 1.5-4.0 months). Nine of 20 evaluable patients (45%; 95% CI, 23.1-68.5%) derived clinical benefit, including 3 partial responses and 6 with stable disease lasting 8 weeks.
Introduction
Tumor molecular profiling represents an essential cornerstone in precision oncology -a therapeutic paradigm which is increasingly based on knowledge of the cancer mutation repertoire and the prescription of drugs that target aberrant genes or pathways.
1,2 Such a strategy is premised on the hypothesis that "targeted therapies" are more likely to benefit patients whose tumors harbor a matching molecular alteration. Indeed, a meta-analysis has recently shown that the deployment of biomarker-guided strategies to facilitate cancer patients' enrollment into early-phase clinical trials are, in the aggregate, associated with improved therapeutic outcomes as compared to non-personalized approaches. 3 However, the clinical application of next-generation sequencing (NGS) to identify potentially actionable molecular alterations is fraught with multiple technical and logistical challenges, thus indicating a continued need to describe institutional efforts to implement precision oncology and to characterize the barriers to enrollment of patients into clinical trials.
The utility of molecular screening protocols to support early phase clinical trial enrollment in Asian cancer patients remains unclear since most precision oncology initiatives have been performed in the United States and Europe in predominantly Caucasian populations. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] However, there is increasing appreciation for ethnogeographical variability in the epidemiology of genomic mutations across diverse populations [14] [15] [16] [17] [18] [19] [20] which may impact the feasibility of accruing patients into biomarker-enriched clinical trials. For instance, "druggable" EGFR kinase domain mutations are established to occur at a much higher incidence in East Asian patients with non-small cell lung cancers compared to patients of European ancestry.
14 Furthermore, other regional differences which have the potential to influence precision oncology programs include disparities in the clinical trial landscape and infrastructure, and the sociocultural attitudes toward genetic testing. Accordingly, the Integrated Molecular Analysis of Cancers (IMAC) study -one of the first molecular screening programs initiated in Asia -was conducted to assess the feasibility of targeted gene sequencing panels to inform treatment decisions, and to establish the prevalence and spectrum of mutations in advanced cancers from Asian patients.
Methods

Patients
The IMAC program prospectively screened patients referred to the Developmental Therapeutics Unit (DTU) at the National University Cancer Institute, Singapore (NCIS). Patients 21 years or older with a histologically confirmed diagnosis of a solid malignancy or lymphoma, and adequate tumor tissue for genomic characterization were eligible for the study, which was approved by the National Healthcare Group-Domain Specific Review Board and the SingHealthCentralized Institutional Review Board (Supplement 1). The study was conducted in accordance with Good Clinical Practice guidelines, and patients provided written informed consent before study entry. The study is registered at clinicaltrials.gov (identifier: NCT02078544).
We established genomic profiles based on fresh-frozen or paraffin-embedded primary tumor and/or metastatic specimens, which were obtained during routine clinical care (e.g., surgery, biopsy or ascites and pleural fluid drain). Patients were also informed of the possibility of detecting incidental somatic mutations that could have implications for their risk of having genetic predisposition syndromes and were asked to opt for whether they or their next of kin were keen to receive additional information and genetic counseling in the event such variants were identified in their tumor specimens. 21 In addition, routine clinicopathological assays, such as immunohistochemistry, copy number analysis (HER2 amplification) and in situ hybridization tests (ALK), were also considered in the tumor molecular profiles of each patient.
Sequencing and bioinformatic analysis
DNA isolation, library preparation and targeted NGS of fifty cancer-related genes were performed per manufacturer's instructions (AmpliSeq Cancer Hotspot Panel v2 on an Ion Torrent/PGM system, Life technologies, Camarillo, CA, USA) (Fig. 1S) . Samples which had sequencing base depth <500, unfiltered DNA variants >100 or uniformity of coverage <80% were excluded from downstream bioinformatics analysis. Pathogenicity of somatic variants was determined through a review of the published literature as well as public curated databases (ClinVar for pathogenicity information; My Cancer Genome for frequency of variant and exon number; Ensembl GRCh37 for the protein domain where variant occurs). In the event that phenotypic information on a rare variant was unavailable from ClinVar or Catalogue of Somatic Mutations in Cancer (COSMIC) databases, the Variant Call Format (VCF) files were processed with Variant Effect Predictor (VEP) version 75 to obtain in silico indices (SIFT and What's new? Variability in genomic mutations across ethnicities and geographical regions potentially complicates clinical trials using predictive and prognostic biomarkers. In this study, the authors review the institutional implementation of a prospective molecular screening protocol in an Asian population. The spectrum and prevalence of somatic mutations was determined. Molecular prescreening was found to be critical to the enrollment of 8 percent of patients into biomarker-enriched clinical trials. About 91 percent of patients indicated interest in being informed of incidental findings. Patients enrolled in trials showed signs of benefit, with a progression-free survival of 2.9 months and clinical benefit rate of 45 percent.
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POLYPHEN) for pathogenicity inference. Because genetic profiling was not performed on paired normal tissue for these patients, we excluded variants with minor allele frequency >5% among East Asians or South Asians in the 1,000 Genomes Database (Fig. S1 ). For the purpose of our study, all exonic non-synonymous alterations which passed the aforementioned quality control and filtering procedures were considered "reportable." As the evidence base for prognostic and predictive molecular biomarkers is in constant flux, we did not employ any prespecified algorithms to prioritize the actionability of reportable variants.
Interventions
A monthly, multidisciplinary molecular tumor board was convened to interpret and deliberate on sequencing results as well as findings from additional routine clinical molecular biomarker results, if available. The tumor board included the IMAC study investigators and additional expertise from clinical geneticists, pathologists, bioinformaticians and oncologists from the National University Cancer Institute, Singapore (NCIS) Developmental Therapeutics Unit (DTU) with tumor site-specific interests. The results of molecular profiling and board recommendations were then conveyed to treating oncologists, who decided whether to enroll patients into clinical trials of targeted therapies. An average of about 140 clinical trials ranging from phase 1 to phase 3 is actively recruiting at our institute annually. Of which, 20% are biomarker selective clinical trials. Patients who were enrolled into clinical trials were followed-up and assessed for tumor response and outcomes according to the study protocols of the respective clinical trials.
Outcomes
The primary outcome was the progression-free survival of patients enrolled in biomarker-driven clinical trials. This was defined as the time from enrolment to radiological or clinical disease progression per RECIST version 1.1 criteria. Secondary outcomes were clinical benefit rate of patients enrolled in biomarker-driven clinical trials, defined as the cumulative rate of complete or partial responses, and stable disease 8 weeks; the turnaround time for molecular report, defined as the duration from sample receipt to return of molecular results; characterization of the mutational landscape of sequenced tumors and the proportion of patients who consented to receiving genetic counseling for incidental genomic findings.
Statistical analysis
Descriptive statistics, including median and interquartile range for continuous variables, and frequencies and percentages for categorical variables, were tabulated and presented as appropriate. Progression-free survival was analyzed by the Kaplan-Meier method. Exact binomial distributions were used to provide 95% confidence intervals for the clinical benefit rate. The Mann-Kendall test was applied to evaluate whether there was a trend in turnaround time over the course of the study. Mutational data were clustered using the GenVisR package in R version 3.4.0 (R project, Institute for Statistics and Mathematics). All other statistical analyses were performed in STATA version 13.0 (STATA Corp., College Station, TX).
Results
Tumor mutational profiles
From April 28, 2014, to September 1, 2016, a total of 479 patients from 15 institutions in South East Asia were referred to the IMAC molecular screening program, and 396 with tumor samples suitable for genomic analysis ( Fig. 1 and Table S1 ). Targeted gene panel testing was successful in 365 of 396 (92%) of patients, achieving a mean depth of 1,9433 and coverage uniformity of 96% (Table S1 ). The final patient population included diverse tumor types, including gynecological (22%), colorectal (21%), lung (13%) and breast cancers (12%) (Fig. 2a) . Details on the sampling procedure and type of tissue used, DNA extraction procedure and sequencing quality metrics are presented in Table S1 .
The median turnaround time from sample receipt to return of genomic results was 26.0 days (IQR, 19.0-39.0 days); the NGS assay and bioinformatics analysis respectively took 14.0 (IQR, 9.0-23.0) and 8.0 (IQR, 6.0-10.0) days (Fig.  S1 ). We observed a decreasing trend in turnaround time for molecular report generation over the course of the study (p < 0.001), which may suggest a technical learning curve in terms of the implementation of new technologies and integrated workflows for NGS and clinical reporting.
One of the study aims was to characterize the prevalence and spectrum of mutations in advanced, refractory tumors from patients of Asian ancestry. Overall, 300 of 365 (82%) patients had at least one reportable genomic mutation in any of 50 cancer-related genes, with 125, 85 and 90 patients harboring one, two or three or more reportable mutations, respectively (Table S2) . Within cancer types, colorectal, lung, head and neck, pancreatic cancer patients carried a median of two reportable alterations, while breast, gastroesophageal, liver and gynecological cancer patients contained a median of one reportable mutation (Table S3 ). The most commonly mutated oncogenes in the overall cohort included KRAS (19%), PIK3CA (16%), EGFR (5%), BRAF (3%) and KIT (3%); while the most frequently mutated tumor suppressor genes included TP53 (40%), SMARCB1 (12%), APC (8%), PTEN (6%) and SMAD4 (5%) (Fig. 2b and Table S4 ).
Altogether, 358 unique mutations across 45 genes were identified, with recurrent mutations detected in TP53, KRAS, SMARCB1, PIK3CA, SMAD4, PTEN, APC, AKT1, ALK, BRAF, CDH1, JAK3, CDKN2A, EGFR, FGFR2, GNAS and NRAS (Table S5) . SMARCB1 T72K mutations were highly recurrent in our study cohort (41/365; 11%), but likely represents an artifactual finding given its localization in the region of a mononucleotide repeat, at which NGS platforms are known to generate errors. 22 Subsequent immunohistochemical analysis of SMARCB1/INI-1 expression in tumors harboring this variant also demonstrated the absence of deleterious effects on protein expression (Fig. S2) . We found that the PIK3CA kinase domain-associated H1047R mutation (16/60; 27%) was more common than the helical domain-associated E545K (12/60; 20%) and E542K (9/60; 15%) mutations among our study population. Notwithstanding the small sample size, TP53 mutations were infrequent in hepatocellular carcinoma (1/11; 9%) and renal cell carcinoma (0/10; 0%). In precision medicine, predictive and prognostic molecular biomarkers are crucial because they have the potential to influence therapeutic decision-making. In our population, 30 of 365 (8%) patients respectively had KRAS G12C or G12V substitutions, which are considered to confer worse prognosis compared to other KRAS mutations in codons 12 and 13 (Table S6) . 23 We also examined the mutational profile of frequently altered genes within individual cancer types. EGFR mutations were mostly confined to lung cancers; on the whole, 15 of 48 (31%) lung tumors were found to harbor at least one reportable mutation in EGFR, reaffirming the high incidence of EGFR-mutant lung cancer in patients of Asian ancestry (Fig. 2c ). 14 Of these, 6 patients had the exon 21 L858R substitution and 8 patients had an exon 19 deletion, which may confer sensitivity to EGFR tyrosine kinase inhibitors (TKIs), although the latter is associated with better clinical outcomes. 24 By inspecting genetic profiles for potential sources of therapeutic resistance to EGFR TKIs among lung cancer patients, we found five patients harbored the EGFR T790M variant, which predicts resistance against firstgeneration EGFR TKIs; 24 three patients had gain-of-function mutations in PIK3CA and one had a PTEN variant at amino acid position 171 which leads to its premature truncation. 24, 25 Furthermore, two lung cancer patients were found to carry ALK G1202R mutations, which is located at the solvent front of the ALK kinase domain and has been shown to drive primary and acquired resistance to most ALK inhibitors currently used in clinical practice or under investigation (e.g., alectinib).
26
In addition, 19 of 43 (44%) breast cancer patients exhibited a PIK3CA mutation, 11 of which were H1047R mutations, which have been reported to be associated with response to PI3K inhibitors in early-phase clinical trials. 27, 28 In total, 19 of 43 (44%) breast cancer patients and 30 of 81 (37%) gynecological cancer patients had reportable PIK3CA or PTEN mutations, of whom, one and four patients had potentially sensitizing mutations to PI3K inhibitors in both genes. [27] [28] [29] We also detected BRAF V600E mutations in 4 of 77 (5%) colorectal cancer patients. Detailed mutational data of our patient population are provided in Table S6 .
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Patient willingness to receive incidental findings to harbor this variant from our study were not associated with MLH-1 protein loss in tumor cells or normal tissue, hence corroborating its ClinVar designation ( Fig. S3) As such, none of our patients have been referred for genetic counseling on the basis of this potential germline polymorphism.
Outcomes of patients matched to biomarker-driven trials
From our NGS results, 23 of 300 (8%) patients with reportable mutations were enrolled in biomarker-enriched clinical trials based on their molecular alterations. Patients enrolled in clinical trials had a median age of 61 years (range, 45-77) and ECOG 0-2, and the majority were females (n 5 15; 63%) The majority of patients were heavily pretreated with a median of 4 (range, 1-11) prior lines of systemic treatment (Table 1 ). Fifteen patients with PIK3CA alterations were treated on biomarker-selected cohort of exportin-1 (XPO1), PI3Ka/b or PI3Ka plus CDK 4/6 inhibitor trials; one AKT mutant endometrial cancer patient was matched to an AKT inhibitor trial; two EGFR mutants to EGFR or HER1/2/4 inhibitor trials; three ALK/ROS1 rearranged patients to ALK or ROS1 inhibitor trials and two KRAS mutants to an XPO-1 inhibitor trial (Table 2) . Among the 23 patients enrolled in genotype-matched trials, median progression-free survival was 2.9 months (IQR, 1.5-4.0 months) (Fig. 3a) . Nine of twenty evaluable patients derived some form of clinical benefit, including 3 partial responses and 6 with stable disease lasting 8 weeks leading to a clinical benefit rate of 45% (95% CI, 23.1-68.5%) ( Table 2) . One patient who was enrolled into a biomarker-driven clinical trial was a 64-year-old woman who had endometrial cancer with lung, liver and sacral metastases. Genomic profiling of a tissue block taken from an anterior resection of her rectum revealed an AKT1 E17K mutation with a variant frequency of 58%. On the basis of these findings, the decision was made to enroll the patient into a pan-AKT inhibitor trial which targets this particular mutation. 35 The patient showed significant clinical improvement and was taken off opioid analgesia for sacral pain. Within 6 weeks of starting therapy, she achieved disease stabilization for >6 months without experiencing major toxic effects (Fig. 3b) . A second example features a patient with metastatic breast cancer (ER 10%, PR and HER2 negative) who had failed multiple lines of prior hormonal and cytotoxic therapy. Her chest nodule biopsy was found to contain PIK3CA H1047R (variant frequency, 41%) and A400V (variant frequency, 50%) mutations, and as a result she was enrolled into a PI3K inhibitor trial. Scans before and after treatment demonstrated a dramatic reduction in chest wall disease (Fig. 3c) . Unfortunately, she progressed on treatment with the development of new liver nodules after 42 days and was taken off-trial.
Discussion
The IMAC study was initiated to address the feasibility and effectiveness of a precision oncology program in an Asian context. A secondary goal in our study was to elucidate the molecular profiles of cancers from Asian patients. We found that molecular profiling provided biologically informative results which facilitated enrollment of 8% of patients into biomarker-enriched clinical trials, which is consistent with the matching rates reported in previous studies. The Princess Margaret IMPACT/COMPACT trial, and the MD Anderson and Memorial Sloan Kettering Cancer Centres report enrolling patients into genomically matched clinical trials at a rate of 5-11%. 5 36 Notwithstanding, direct comparisons to these aforementioned studies are challenging given the differences in drugs that were used, distinct ethnic composition of patients, and the fact that patients in our study were enrolled into early-phase clinical trials where safety is the primary endpoint, thus precluding any wellcontrolled comparison of the efficacy of targeted agents. In our study, we observed a high rate of consent for receiving incidental findings relevant to genetic predisposition syndromes (91%). To our knowledge, there has not been any previous data addressing this question from the patient's perspective in Asia. This is an important observation for our study and has ethical implications for genomic data from future prospective "omic" studies in Asia where germline DNA is likely to be sequenced in conjunction with tumor DNA. Studies done in ethnic minorities in the United States and Australia suggest that negative attitudes and concerns about confidentiality, stigma and discrimination may be present, although patients generally acknowledged the other benefits of acquiring these information. 37 Although the American College of Medical Genetics advocates the return of incidental genetic findings, 21 there are several unresolved challenges especially pertaining to the clinical relevance of potential germline variants. In particular, the recurrent MLH1 V384D substitution in our study provides an interesting example of unique issues that may be encountered with precision oncology in different ethnic groups, and highlights the need for greater efforts to collate reports and genomic databases from different ethnic populations. We found that the timeframe for return of molecular report was, on the whole, acceptable, as the turnaround time generally decreased over the course of the study. An improvement in turnaround time was also reported by Mody et al. 38 although not by the SAFIR-01 investigators, 13 and may be attributed to an initial learning curve for NGS technologies and downstream bioinformatics analysis or early bottlenecks in the establishment of integrated workflows. In our study, possible explanations for our improved turnover time would have included hiring more laboratory manpower, having dedicated personnel and equipment for the IMAC program, streamlining the process of archival sample procurement, dividing some of the DNA extraction procedures between two laboratories (the Centre for Translational Research and Diagnostics and the Diagnostic Molecular Oncology Centre). Here, we did not employ a prespecified algorithm for prioritization of somatic mutations or enrollment into drug trials unlike several previous precision oncology initiatives. 6, 10, 36 Instead, individual patient tumors were reviewed and discussed on a case-by-case basis at a molecular tumor board, for clinical evidence linking their alterations to drug response or resistance.
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In our study, we excluded variants with MAF >5% (in the East and South Asian populations) in the 1,000 Genomes Database. This concept of filtering variants based on their allele frequency, in the absence of paired normal tissue, was also performed in other recent precision oncology initiatives. 20 We concede that one consequence of this filtering procedure is the potential for true somatic variants to have been excluded. However, by virtue of the fact that these "potentially-missed" true somatic variants can also be found at considerable allelic frequency as a germline polymorphism in healthy normal populations, they would likely represent benign or non-pathogenic variants, thus their exclusion is unlikely to cause investigators to miss out on potentially actionable findings. Another implication of not performing analysis of paired normal samples is the resultant lower costs and feasibility of genomic sequencing, which may increase the uptake of precision oncology approaches.
Evaluating the clinical utility of large-scale genetic testing is challenging. We primarily captured information regarding the enrollment rate into biomarker-driven clinical trials, patients' clinical outcomes, and the spectrum and diversity of reportable mutations in an Asian population including At the time of conceptualization, we opted to perform multiplex hotspot sequencing of only 50-cancerrelated genes to balance the costs of NGS against the incremental benefits of using a wider platform for biomarker identification. 10 This may have limited our ability to characterize the full repertoire and incidence of potentially actionable mutations in our cohort of Asian patients. The findings from our study should also be interpreted with caution given its single-arm nature, but nonetheless represents one of the largest precision oncology cohorts to date in Southeast Asia. Nevertheless, we have demonstrated that the ability to rapidly probe the molecular landscape of tumors will facilitate the translation of these findings to the oncology clinic with preliminary evidence of efficacy in selected patients. We anticipate that a more customized approach to cancer care within Asia will require larger scale collaborative initiatives of this nature in the future. Of note, however, the high cost of molecular profiling would prohibit widespread dissemination of this precision oncology approach in Asia. Thus, support from health authorities and insurance companies would be required to allow for wider use of these molecular tests in clinical practice. As the repertoire of targeted drugs increases and sequencing technologies become more readily available along with increasing awareness and reducing cost of targeted molecular profiling, the uptake of such approaches will slowly increase. Based on current evidence, these approaches should be developed in the context of academic trial centers with access to appropriately matched clinical trials.
In conclusion, the IMAC precision oncology study establishes that in an Asian context, prospective molecular prescreening to facilitate patient enrollment into clinical trials is feasible. This is substantiated by the high incidence of potentially actionable findings in our study cohort, the reasonable turnaround time for return of results, and the promising signals of clinical benefit among patients enrolled into earlyphase clinical trials of investigational targeted therapies. Moreover, the notion of receiving incidental findings was well-received by patients.
